Valerie Seagroatt

It has been hypothesised that the measles, mumps, and rubella vaccine (MMR vaccine) increases the risk of autism and Crohn's disease. Although a possible link with autism has been extensively studied and refuted,1 a link with Crohn's disease has not. I tested this hypothesis by analysing trends in age specific admission rates for Crohn's disease in children and adolescents to determine if the introduction of MMR vaccine in 1988 increased rates in those populations that were offered the vaccine as infants.

Methods and results
Counts of admissions, taken as the first consultant episode in a hospital stay, in patients aged ≤18 years with a main diagnosis of Crohn's disease in England (population 50 million) were available for the 12 years from April 1991 to March 2003.2 I restricted the analysis to emergency admissions as these were probably less susceptible to changes in thresholds for admission and clinical practice than elective admissions. In the first two years of the MMR vaccination programme, the percentages of children completing a primary course of MMR vaccine in their second year of life were 7% and 68%; thereafter the percentage was at least 84%.3

Initially, temporal trends in age specific rates were plotted, differentiating between the rates for those born before and after the introduction of the vaccine. (Rates for patients aged 16 to 18 years—too old to have been offered vaccine as infants—provided information on underlying trends unaffected by MMR vaccination in infancy.) Data for those born in 1987-8, of whom only 68% were vaccinated as infants, were excluded from the analysis. The MMR vaccination programme was then modelled as a variable with two levels (vaccination rate of ≥84% and of ≤7%) using Poisson regression, with adjustment for year of admission and age in single years (as categorical variables).

There were 4403 admissions for Crohn's disease, 923 of which occurred in populations with a vaccination rate of ≥84% (those born in 1988-9 or later). Although the age specific rates increased over the study period, no obvious changes occurred that coincided with the introduction of MMR vaccine (figure). The estimated rate ratio for the MMR vaccination programme (rates in populations with a vaccination rate of ≥84% compared with those with a rate of ≤7%) was 0.95 (95% confidence interval 0.84 to 1.08).

Comment
The introduction of MMR vaccine, replacing the single measles vaccine, was not associated with an increase in Crohn's disease. Given the precision of the rate ratio, all but a small risk would have been detected. This was an ecological study, and findings from such studies generally need to be treated cautiously because of...
What is already known on this topic

It has been hypothesised that the measles, mumps, and rubella vaccine (MMR vaccine) increases the risk of Crohn’s disease, though the evidence base for this hypothesis is sparse.

What this study adds

An ecological analysis of national data on hospital admissions found no increase in Crohn’s disease associated with the introduction of the MMR vaccination programme, providing strong evidence against the hypothesis that MMR vaccine increases the risk of Crohn’s disease.

Potential for confounding. Could the negative finding from this analysis be due to confounding? If so, some factor(s) would have to be negatively associated with Crohn’s disease, be introduced over the same three year period, and be targeted at the same population of infants as MMR vaccine to mask a true association. This seems highly unlikely.

A smaller ecological study and two case-control studies also found no increased risk of Crohn’s disease associated with MMR vaccine.

Initially, measles vaccine was reported to be associated with higher rates of Crohn’s disease, but this was not confirmed by subsequent studies. Natural infections with measles and mumps within one year were also associated with an increased risk of Crohn’s disease. Although that finding has yet to be confirmed, it raised the possibility that infections with multiple viruses in MMR vaccine might increase the risk of Crohn’s disease. My study provides strong evidence against that hypothesis and adds to the evidence that MMR vaccine is no less safe in this respect than the single measles vaccine.

The gold standard: not a golden standard

Studies that evaluate a new diagnostic test, procedure, or method should do so by comparing it with a time honoured alternative that is considered to be the current standard in the field. In this context the meaning of the word standard is “authoritative or recognised exemplar of quality or correctness.” “Gold standard” is the popular term to describe this test; but “golden standard” is sometimes used as well. In fact, almost all medical publications in Dutch use the term “goedkundig” which is a translation of “gold standard.” Apparently, medical scientists have become confused about the true meaning of the term gold standard.

Inspired by the Olympic Games, where the best athlete wins the gold medal, and then to replace it with “golden,” which simply sounds better if English is not your first language. In addition, the gold medalist is an “individual,” and then to replace it with “golden,” which simply sounds better if English is not your first language. In addition, “golden standard” is a persuasive term that makes sense: if a standard denotes the best standard in the world. Not bronze, not silver, but gold. Of course, this is incorrect.

Gold standard is a historical term borrowed from economists. It signifies a monetary standard, under which the basic unit of currency was defined by a stated quantity of gold. The analogy should be clear: the value of each country’s method of payment (currency) was weighed against the gold standard, which made it possible to compare these different currencies for international trading.

In a Medline search from 1955 onwards, the first emergence of the term—albeit in a different meaning—was in 1962, in an anonymous commentary in the Lancet. Entitled “Towards a gold standard,” it pleaded to set a standard for the use of gold salts in patients with rheumatoid arthritis. It may well have been Rudd who first introduced the “gold standard” in medicine in its current sense in 1979. In the following years, the number of publications that employed the term grew rapidly. This was much to the dismay of one biochemist, who thought the term was “presumptuous” for a biological test, since “the subject is in perpetual evolution [and] gold standards are by definition never reached.” He proposed abolishing the term “because the phrase smacks of dogma …After all, the financiers gave up on the idea of a gold standard decades ago.” He failed in his mission, however: since 1995, over 10 000 publications mentioned “gold standard.”

So why is there also a “golden standard,” a term used in over 600 publications since 1995 in English and in many more in foreign languages? I think this is because it is tempting to interpret the word “gold” in gold standard as an adjective, as in gold medal, and then to replace it with “golden,” which simply sounds better if English is not your first language. In addition, “golden standard” is a persuasive term that makes sense: if a standard is the one test by which all others are judged, then the golden standard must be perfect.

Herein lies, I think, the importance of this discussion. The concept of a “golden standard” implies a level of perfection that can never be attained by any biological test, and will provoke criticism like that ventilated by Duggan. In contrast, a gold standard in its true meaning, derived from the monetary gold standard, merely denotes the best tool available at that time to compare different measures. Even in its glory days, the monetary gold standard was never considered perfect. It was subject to endless debate, and in the end it was abandoned for a better system. Similarly, today’s gold standard tests will be replaced by better ones. As was eloquently stated by Versi: “It is the absolute truth that is never reached; gold standards are constantly challenged and superseded when appropriate.”

Jurgen A H R Claassen consultant geriatrician, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands (j.claassen@ger.r模拟.nld)

References